

Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

For the period: 1 January 2022 - 31 December 2022

Company: Novartis Pharmaceuticals Australia Pty Ltd

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Allergy & Anaphylaxis Australia	Support towards the creation and distribution of the Allergic Asthma Brochure.	\$10,000
Allergy & Anaphylaxis Australia	Support towards the creation and distribution of the Urticaria Brochure.	\$5,000
Australian Sickle Cell Advocacy Inc	Support towards the 2nd Australian Sickle Cell Advocacy Conference which is a one day event to: -provide mental health resources to patients/caretakers, -highlight screening & treatment, -advocate for a national surveillance database, and -raise awareness to all stakeholders.	\$12,500
Deakin University Australia	Support towards I-HEART, the implementation of Heart Failure guidelines in Regional Australia. This project proposes a new system of care to improve the translation of guidelines into practice and equity in access to a HF specialist team. I-HEART is an innovative system of care comprised of key recommendations from the HF guidelines where the evidence of their benefits in reducing preventable rehospitalisations and saving lives is so strong that patients cannot be denied access to these vital interventions. Using a translational science methodology, the implementation of I-HEART will be co-designed by clinicians, consumers and health service executive at six regional health services. The effectiveness of I-HEART will be determined in a stepped wedge cluster randomised trial. Over a five-year period, it will address inequity in access to specialist services in regional health services, particularly over the most vulnerable phase of 30 days postdischarge when patients are highly likely to be rehospitalised.	\$7,000
Hearts4Heart	Support towards a medical writer to assist with the development and repurposing of content for the hearts4heart website to broaden its remit to include structural heart disease in the areas of heart failure and heart valves.	\$30,734
ITP Australia Ltd	Support towards the following planned ITP Australia activities: - Annual Patient Conference - National ITP Clinician Survey - Digital Patient Collateral - Clinician Register on the ITP Australia website - Patient Roadshow in NSW, ACT & SA - Quarterly Patient Newsletter - ITP Awareness Month Virtual Town Hall Meeting - Email marketing initiatives to patients and registered members	\$50,000
Leukaemia Foundation of Australia Limited	Support towards the clinical review of Myeloproliferative neoplasms (MPN) content and development of patient information and education for people living with MPN and Myelofibrosis (MF). This includes updating of MPN digital booklets and printing of MPN disease booklets for dissemination to all major treating centres in Australia.	\$20,000
Lung Foundation Australia	Support towards the Australian Lung Cancer Conference 2023 designed to provide macro and micro perspective through keynotes, plenaries, panel presentations, walk throughs and many other mechanisms that will suit the varied needs of attendees.	\$10,000
Lymphoma Australia	Support towards three nurse educational events in Diffuse large B cell lymphoma (DLBCL) & Chimeric Antigen Receptor (CAR) T-cell therapy to improve patient support and share best practices.	\$18,000

Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

For the period: 1 January 2022 - 31 December 2022

Company: Novartis Pharmaceuticals Australia Pty Ltd

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Macular Disease Foundation Australia	<p>Support towards an innovative pilot project that aims to improve IVI treatment adherence. A critical success factor for this project will be scoping out the technology needed to scale up to a national program and developing educational resources to support and motivate IVI treatment adherence.</p> <p>There are four parts to this initiative:</p> <ol style="list-style-type: none"> 1. Undertake a literature review of all studies of vision impairment induced depression and anxiety and assess recommended interventional themes. 2. Co-design and co-develop a suite of resources/interventions for patients with AMD. 3. Deliver and distribute resources/pilot interventions. 4. Evaluation to inform improvements or next steps 	\$115,000
Melanoma and Skin cancer Advocacy Network	<p>Support towards developing and launching a series of education modules that aim to develop the knowledge of nurses that are working in melanoma and non-melanoma skin cancer.</p>	\$9,620
Melanoma and Skin cancer Advocacy Network	<p>Support towards reviewing developed Nurse Modules with the aim to:</p> <ol style="list-style-type: none"> 1. To understand the key educational gaps for melanoma nurses in Australia, and how this impacts patient care 2. To determine which key resources melanoma nurses refer to for up-to-date evidence based material for upskilling in the therapeutic area 3. To understand the role of melanoma nursing in the optimal care and management of patients on melanoma systemic therapy 	\$16,695
Melanoma and Skin cancer Advocacy Network	<p>Support towards the research, scope and design of a skin cancer nurse-to-nurse support model. More specifically, the project will look at how highly experienced nurses can be engaged to support nurses around the country to ultimately improve patient care. The model would primarily focus on nurse-to-nurse education, training and best practice and provide a centralised, evidence-based source of information for nurses.</p> <p>The primary deliverable of this project will be a report that outlines what a national skin cancer nurse-to-nurse support model could look like.</p> <p>This will include the supporting research that explains how the model could work including:</p> <ul style="list-style-type: none"> • The benefits to patients • The benefits to the healthcare system broadly (exploring cost savings; the early detection of adverse events from treatment; and a reduction in the numbers of patients that need to be hospitalised as they can be appropriately managed with skilled nurses) • The impact of an upskilled nursing workforce • The benefit to the nursing workforce of having a collaborative, supportive model that also considers the wellbeing of nurses • An assessment of both the financial and non-financial benefits it would bring • The anticipated set up and running costs. 	\$20,000
Melanoma Patients Australia	<p>Support towards a Consumer Roundtable Discussion with key Melanoma stakeholders and the creation of a Melanoma Toolkit including key resources for consumers.</p>	\$40,000
Multiple Sclerosis Australia	<p>Support towards the development of the MS Australia Clinical Trails Network which lists clinical trials and research studies in MS in Australia and New Zealand that people with MS can independently seek out and participate in. This network was established to encourage high-quality clinical MS research in Australia and to increase awareness of clinical trials and research studies for people with MS.</p>	\$25,000
Myeloma Foundation of Australia	<p>Support towards the 4th National Myeloma Scientific Workshop which is a 3 day event to bring together researchers from basic science, translational and clinical medicine and nursing to explore new ideas in the pathophysiology and treatment of multiple myeloma.</p>	\$10,000
Neuroendocrine Cancer Australia	<p>Support towards the Neuroendocrine Cancer Australia National Theranostics Round Table and developing Neuroendocrine Cancer Australia's (NECA) NET education modules directed to nurses and General Practitioners.</p>	\$15,000

Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

For the period: 1 January 2022 - 31 December 2022

Company: Novartis Pharmaceuticals Australia Pty Ltd

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Pink Hope Community Ltd	Support towards a pre-campaign survey, new breast check video, and digital activation across Pink Hope platforms and launching a Breast Cancer Awareness Campaign to remind and educate the community to be vigilant about your breast health.	\$51,000
Pink Hope Community Ltd	Support towards a table for Novartis at the Pink Hope Community Impact Dinner 2022, a fundraising program	\$2,750
Psoriasis Australia Inc	Support towards raising awareness of Psoriatic disease and support activities associated with World Psoriasis Day 2022	\$22,750
Rare Cancers Australia Ltd	Support towards CanForum 2022 which gathers unique perspectives of leading experts and patient advocates as we seek to change the way we think about the cost of medicines, and the value of a life. Furthermore, the Australian Government is reviewing the system we use for assessing new medicines, including for people with cancer. This assessment affects whether every Australian diagnosed with cancer has timely and affordable access to the medicines they need.	\$40,000
Rare Voices Australia Ltd	Support towards Rare Voices Australia's (RVA) Quarterly Round Table of Companies which is a group of pharmaceutical companies with a common interest in rare diseases and orphan drug development. The quarterly meetings and workshops bringing together stakeholders to discuss topics relevant to the development of treatments for rare diseases.	\$5,000